Research analysts covering Lexaria Bioscience.
Recent press releases and 8-K filings for LEXX.
Lexaria Bioscience Corp. Closes $4.0 Million Registered Direct Offering
LEXX
New Projects/Investments
- Lexaria Bioscience Corp. announced and closed a $4.0 million registered direct offering and concurrent private placement on September 29, 2025.
- The offering included the sale of 2,666,667 shares of common stock at $1.50 per share.
- Concurrently, the company issued 2,666,667 unregistered warrants to purchase common stock, with an exercise price of $1.37 per share.
- The net proceeds from the offering are intended for working capital and general corporate purposes, including 2026 R&D and business development plans.
Sep 29, 2025, 9:05 PM
Lexaria Bioscience Raises $4 Million via Offering
LEXX
- Lexaria Bioscience Corp. announced a registered direct offering to sell approximately 2.67 million shares of common stock at $1.50 per share, expecting to raise about $4 million for working capital and general corporate purposes.
- The offering also includes unregistered warrants exercisable at $1.37 per share. This follows the termination of a prior sales agreement that had raised only $38,236.
- Despite facing significant financial challenges, including a negative operating margin of -1849.84% and a 3-year revenue decline rate of -39.2%, Lexaria's shares surged 32% in premarket trading.
- The company maintains a strong balance sheet with a current ratio of 3.9 and a low debt-to-equity ratio of 0.02, and analysts currently rate the stock as a Buy with a $4.00 price target.
Sep 26, 2025, 1:32 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more